Hongjuan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hongjuan Yu has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Weidong Huang
School of Health Management, Harbin Medical University, Harbin, China
10 shared publications Haofei Li
School of Health Management, Harbin Medical University, Harbin, China
8 shared publications- Weidong Huang
School of Health Management, Harbin Medical University, Harbin, China
7 shared publications Yiyin Cao
School of Health Management, Harbin Medical University, Harbin, China
6 shared publicationsNan Luo
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
5 shared publicationsLemin Wu
School of Health Management, Harbin Medical University, Harbin, China
4 shared publications
Latest Publications
- 6 November 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (11) , 321
Developing a Chinese value set for the FACT-8D, a cancer-specific multi-attribute utility instrument based on the FACT-general (FACT-G) questionnaire
- 6 November 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (11) , 321
Developing a Chinese value set for the FACT-8D, a cancer-specific multi-attribute utility instrument based on the FACT-general (FACT-G) questionnaire
- 10 September 2026
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- p. 1-14
Treatment Preferences for Acute Myeloid Leukemia in Harbin, China: A Discrete Choice Experiment Among Patients, Caregivers, and Hematologists
Objective This study aimed to quantify the preferences and trade-offs of Chinese patients with acute myeloid leukemia (AML), primary caregivers, and hematologists regarding key treatment attributes, and to explore heterogeneity in preferences across and within groups. Methods A discrete choice experiment with five attributes (complete remission rate, quality of life during treatment, long-term side effects, route of administration, and monthly treatment cost) was conducted. Between November 2025 and February 2026, patients with AML and their caregivers were recruited from two tertiary hospitals in Harbin, China; hematologists were recruited via an online survey. Preference weights were estimated using conditional logit models. Relative attribute importance and willingness to pay (WTP) were calculated, and preference heterogeneity was examined using a hierarchical Bayes model. Results In total, 109 patients, 112 caregivers, and 85 hematologists were included. All three groups ranked complete remission rate as the most important attribute. Hematologists' WTP for an improvement in remission rate from 65% to 80% (CNY 50,410) was approximately twice that of patients (CNY 25,890) and caregivers (CNY 23,360). Preference weights and WTP for quality of life during treatment were comparable across groups. Patients and caregivers placed greater relative importance on monthly treatment cost (both 21%) than did hematologists (17%). Probability simulations showed that patients and caregivers shifted more strongly toward regimens with more favorable quality-of-life and side-effect profiles as these advantages increased, whereas hematologists showed a smaller change in choice probability. Subgroup analyses indicated that income, prior treatment experience, education level, and residential area were significant sources of preference heterogeneity among patients and caregivers. Conclusions AML patients, caregivers, and hematologists consistently prioritized treatment efficacy but differed in the trade-offs made between remission benefit and economic burden. Shared decision making in AML should integrate quality of life, economic affordability, and long-term side effects, and account for individual variation in patient and family values.
- 10 September 2026
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- p. 1-14
Treatment Preferences for Acute Myeloid Leukemia in Harbin, China: A Discrete Choice Experiment Among Patients, Caregivers, and Hematologists
Objective This study aimed to quantify the preferences and trade-offs of Chinese patients with acute myeloid leukemia (AML), primary caregivers, and hematologists regarding key treatment attributes, and to explore heterogeneity in preferences across and within groups. Methods A discrete choice experiment with five attributes (complete remission rate, quality of life during treatment, long-term side effects, route of administration, and monthly treatment cost) was conducted. Between November 2025 and February 2026, patients with AML and their caregivers were recruited from two tertiary hospitals in Harbin, China; hematologists were recruited via an online survey. Preference weights were estimated using conditional logit models. Relative attribute importance and willingness to pay (WTP) were calculated, and preference heterogeneity was examined using a hierarchical Bayes model. Results In total, 109 patients, 112 caregivers, and 85 hematologists were included. All three groups ranked complete remission rate as the most important attribute. Hematologists' WTP for an improvement in remission rate from 65% to 80% (CNY 50,410) was approximately twice that of patients (CNY 25,890) and caregivers (CNY 23,360). Preference weights and WTP for quality of life during treatment were comparable across groups. Patients and caregivers placed greater relative importance on monthly treatment cost (both 21%) than did hematologists (17%). Probability simulations showed that patients and caregivers shifted more strongly toward regimens with more favorable quality-of-life and side-effect profiles as these advantages increased, whereas hematologists showed a smaller change in choice probability. Subgroup analyses indicated that income, prior treatment experience, education level, and residential area were significant sources of preference heterogeneity among patients and caregivers. Conclusions AML patients, caregivers, and hematologists consistently prioritized treatment efficacy but differed in the trade-offs made between remission benefit and economic burden. Shared decision making in AML should integrate quality of life, economic affordability, and long-term side effects, and account for individual variation in patient and family values.
- 8 March 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (4) , 93
Cancer-specific or generic preference-based measures in oncology? A validity comparison across six commonly diagnosed cancers
- 8 March 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (4) , 93
Cancer-specific or generic preference-based measures in oncology? A validity comparison across six commonly diagnosed cancers
- 10 November 2025
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 27 (4) , 843-855
Quality of life utility-Core 10 dimensions (QLU-C10D) scores based on cancer patients’ health preferences are more sensitive than those based on general public’s health preferences
Objective This study aimed to develop a value set for the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Utility-Core 10 Dimensions (QLU-C10D) based on the preferences of Chinese cancer patients, and to compare results with the Chinese general population value set. Methods Patients with mixed cancer diagnoses were recruited from two hospitals in China between September and November 2024. Patients completed the EORTC Core Quality of Life Questionnaire (QLQ-C30) followed by a discrete choice experiment (DCE) valuation survey consisting of 16 choice sets through face-to-face interviews. A conditional logit model was applied to analyze patient preferences. The characteristics and sensitivity of the derived QLU-C10D value set were compared with those of the Chinese general population QLU-C10D value set. Sensitivity was evaluated by ability to discriminate cancer stage and performance status, and effect sizes (ES) were estimated. Results Data from 659 cancer patients were analyzed. The cancer patients’ value set showed a broader utility range (-0.092 to 1.0) compared to the general population’s value set (0.083 to 1). The mean utility score for the cancer patient sample (0.656) was significantly lower than that for the general population (0.738, P < 0.01). Both value sets demonstrated good sensitivity, but the cancer patients’ value set was more effective in distinguishing clinical subgroup differences (ES = 2.76–4.46 vs. ES = 2.47–3.48). Conclusion Differences in value sets between cancer patients and the general population underscore the importance of more comprehensively integrating patient perspectives into existing evaluation frameworks.
- 10 November 2025
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 27 (4) , 843-855
Quality of life utility-Core 10 dimensions (QLU-C10D) scores based on cancer patients’ health preferences are more sensitive than those based on general public’s health preferences
Objective This study aimed to develop a value set for the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Utility-Core 10 Dimensions (QLU-C10D) based on the preferences of Chinese cancer patients, and to compare results with the Chinese general population value set. Methods Patients with mixed cancer diagnoses were recruited from two hospitals in China between September and November 2024. Patients completed the EORTC Core Quality of Life Questionnaire (QLQ-C30) followed by a discrete choice experiment (DCE) valuation survey consisting of 16 choice sets through face-to-face interviews. A conditional logit model was applied to analyze patient preferences. The characteristics and sensitivity of the derived QLU-C10D value set were compared with those of the Chinese general population QLU-C10D value set. Sensitivity was evaluated by ability to discriminate cancer stage and performance status, and effect sizes (ES) were estimated. Results Data from 659 cancer patients were analyzed. The cancer patients’ value set showed a broader utility range (-0.092 to 1.0) compared to the general population’s value set (0.083 to 1). The mean utility score for the cancer patient sample (0.656) was significantly lower than that for the general population (0.738, P < 0.01). Both value sets demonstrated good sensitivity, but the cancer patients’ value set was more effective in distinguishing clinical subgroup differences (ES = 2.76–4.46 vs. ES = 2.47–3.48). Conclusion Differences in value sets between cancer patients and the general population underscore the importance of more comprehensively integrating patient perspectives into existing evaluation frameworks.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 3453-3467
Residents’ Preferences for Inclusive Commercial Health Insurance: A Comparative Study of Discrete Choice Experiment and Best–Worst Scaling in Heilongjiang Province, China
Objective: The primary objective of this study is to evaluate residents’ preferences for inclusive commercial health insurance to inform policy optimization, as well as to assess the applicability of the Best-Worst Scaling (BWS) and Discrete Choice Experiments (DCE) methods. Methods: A face-to-face survey incorporating both DCE and BWS tasks was conducted with residents recruited in Heilongjiang Province, China. The attributes include insurance liability, premium, reimbursement ratio, deductible, government involvement, and payment methods. Data from BWS and DCE tasks were analyzed using mixed logit and conditional logit models to estimate preference weights for each attribute level. The optimal measurement method was evaluated based on internal consistency, validity, and acceptability. Results: A total of 415 respondents were included in the analysis. Comparative analysis of DCE and the BWS methodologies revealed a pronounced preference among respondents for a 90% reimbursement rate and a streamlined, one-stop claims settlement process. However, notable discrepancies emerged in the ranking of preferences for other attributes. Further analysis indicated a correlation between the preference weights derived from the two methods, although the concordance was only moderate. Additionally, the DCE method demonstrated superior validity and reliability compared to BWS-2. Conclusion: This study reveals residents’ preferences for inclusive commercial health insurance (ICHI), providing valuable insights for optimizing product design and informing policy development. It also provides the first comparative analysis of DCE and BWS methods in the context of ICHI, which validates the superior applicability of DCE for health insurance, offering new perspectives and methodological guidance for future studies.
- 1 November 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 3453-3467
Open AccessResidents’ Preferences for Inclusive Commercial Health Insurance: A Comparative Study of Discrete Choice Experiment and Best–Worst Scaling in Heilongjiang Province, China
Objective: The primary objective of this study is to evaluate residents’ preferences for inclusive commercial health insurance to inform policy optimization, as well as to assess the applicability of the Best-Worst Scaling (BWS) and Discrete Choice Experiments (DCE) methods. Methods: A face-to-face survey incorporating both DCE and BWS tasks was conducted with residents recruited in Heilongjiang Province, China. The attributes include insurance liability, premium, reimbursement ratio, deductible, government involvement, and payment methods. Data from BWS and DCE tasks were analyzed using mixed logit and conditional logit models to estimate preference weights for each attribute level. The optimal measurement method was evaluated based on internal consistency, validity, and acceptability. Results: A total of 415 respondents were included in the analysis. Comparative analysis of DCE and the BWS methodologies revealed a pronounced preference among respondents for a 90% reimbursement rate and a streamlined, one-stop claims settlement process. However, notable discrepancies emerged in the ranking of preferences for other attributes. Further analysis indicated a correlation between the preference weights derived from the two methods, although the concordance was only moderate. Additionally, the DCE method demonstrated superior validity and reliability compared to BWS-2. Conclusion: This study reveals residents’ preferences for inclusive commercial health insurance (ICHI), providing valuable insights for optimizing product design and informing policy development. It also provides the first comparative analysis of DCE and BWS methods in the context of ICHI, which validates the superior applicability of DCE for health insurance, offering new perspectives and methodological guidance for future studies.
- 10 October 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (11) , 3167-3180
Developing a patient-based utility value set for the EORTC QLU-C10D using the OPUF method in Chinese cancer patients
- 10 October 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (11) , 3167-3180
Developing a patient-based utility value set for the EORTC QLU-C10D using the OPUF method in Chinese cancer patients
- Open Access
- 23 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1657249
Assessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China
Objective: This study aimed to evaluate the reliability and responsiveness of the SF-6Dv2, and to provide the first comparative assessment of its validity against the EQ-5D-5L in Chinese patients with colorectal cancer (CRC).Methods: A cross-sectional survey was conducted between August 2022 and December 2023 in three tertiary hospitals in Harbin, China. Eligible CRC patients completed face-to-face baseline interviews to collect demographics, health behaviors, clinical characteristics, EQ-5D-5L, and SF-6Dv2. Follow-up surveys were administered at 7 days and 3 months to collect self-reported health changes and SF-6Dv2. Ceiling and floor effects were assessed by calculating the proportion of respondents reporting the best and worst possible health states. Convergent validity was assessed using Spearman’s correlation with EQ-5D-5L as the reference. Known-groups validity was examined by comparing utility scores across groups categorized by health behaviors and clinical characteristics, testing effect size (ES) and relative efficiency (RE). Agreement was examined using intraclass correlation coefficients (ICC) and Bland-Altman plot. Test-retest reliability of SF-6Dv2 utility and dimension scores was evaluated using ICC and Gwet’s AC over 7 days. Responsiveness was assessed using standardized response mean (SRM) over 4 months.Results: Baseline included 287 CRC patients; 131 and 111 completed first and second follow-ups. A higher ceiling effect was observed in EQ-5D-5L than in SF-6Dv2 (16.7% vs 3.1%). The Spearman correlation between EQ-5D-5L and SF-6Dv2 utility scores was 0.716 (dimensions: 0.313-0.675). Utility scores from EQ-5D-5L and SF-6Dv2 showed moderate agreement (ICC = 0.686). SF-6Dv2 showed superior known-groups validity in surgical treatment (RE = 1.796) and ECOG groups (RE = 1.953). SF-6Dv2 demonstrated excellent test-retest reliability for utility scores (ICC = 0.866), with Gwet’s AC across dimensions (0.322-0.669). SF-6Dv2 showed greater responsiveness in the worsened group (SRM = 0.788) compared to the improved group (SRM = 0.687).Conclusions: SF-6Dv2 showed comparable reliability and responsiveness when used in patients with CRC, out-performing EQ-5D-5L in differentiating clinical known-groups and showing promise for cancer practice and research.
- 23 September 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1657249
Open AccessAssessing the reliability and responsiveness of the SF-6Dv2 and comparing its validity to the EQ-5D-5L among colorectal cancer patients in China
Objective: This study aimed to evaluate the reliability and responsiveness of the SF-6Dv2, and to provide the first comparative assessment of its validity against the EQ-5D-5L in Chinese patients with colorectal cancer (CRC).Methods: A cross-sectional survey was conducted between August 2022 and December 2023 in three tertiary hospitals in Harbin, China. Eligible CRC patients completed face-to-face baseline interviews to collect demographics, health behaviors, clinical characteristics, EQ-5D-5L, and SF-6Dv2. Follow-up surveys were administered at 7 days and 3 months to collect self-reported health changes and SF-6Dv2. Ceiling and floor effects were assessed by calculating the proportion of respondents reporting the best and worst possible health states. Convergent validity was assessed using Spearman’s correlation with EQ-5D-5L as the reference. Known-groups validity was examined by comparing utility scores across groups categorized by health behaviors and clinical characteristics, testing effect size (ES) and relative efficiency (RE). Agreement was examined using intraclass correlation coefficients (ICC) and Bland-Altman plot. Test-retest reliability of SF-6Dv2 utility and dimension scores was evaluated using ICC and Gwet’s AC over 7 days. Responsiveness was assessed using standardized response mean (SRM) over 4 months.Results: Baseline included 287 CRC patients; 131 and 111 completed first and second follow-ups. A higher ceiling effect was observed in EQ-5D-5L than in SF-6Dv2 (16.7% vs 3.1%). The Spearman correlation between EQ-5D-5L and SF-6Dv2 utility scores was 0.716 (dimensions: 0.313-0.675). Utility scores from EQ-5D-5L and SF-6Dv2 showed moderate agreement (ICC = 0.686). SF-6Dv2 showed superior known-groups validity in surgical treatment (RE = 1.796) and ECOG groups (RE = 1.953). SF-6Dv2 demonstrated excellent test-retest reliability for utility scores (ICC = 0.866), with Gwet’s AC across dimensions (0.322-0.669). SF-6Dv2 showed greater responsiveness in the worsened group (SRM = 0.788) compared to the improved group (SRM = 0.687).Conclusions: SF-6Dv2 showed comparable reliability and responsiveness when used in patients with CRC, out-performing EQ-5D-5L in differentiating clinical known-groups and showing promise for cancer practice and research.
- Open Access
- 1 October 2024
- Published by Springer Nature in Health Economics Review
- Vol. 14 (1) , 1-10
A comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances
To perform a comparison of the measurement properties of two cancer-specific Multi-Attribute Utility Instruments (MAUIs), EORTC QLU-C10D and FACT-8D, in Chinese patients with hematologic malignancies (HM). We conducted a longitudinal study on patients with HM in China, using QLU-C10D and FACT-8D at baseline and follow-up (3–4 months from baseline). We assessed: (i) convergent validity using Spearman’s rank correlation test (r) with EQ-5D-5L; (ii) clinical-groups validity by differentiating cancer stages, overall health assessment (OHA), Eastern Cancer Oncology Group (ECOG) performance status, and mental health status. We also examined clinical validity with effect size (ES) and relative efficiency (RE); (iii) responsiveness to changes in patient self-perception using receiver operating characteristics (ROC) curves and area under the curves (AUC); and (iv) agreement using intraclass correlation coefficients (ICC) and visualized with Bland-Altman plot. Among the 308 patients with HM at baseline, 131 completed the follow-up survey. Agreement between the two measures was high (ICC = 0.76). Both measures were highly correlated with EQ-5D-5 L and significantly differentiated (p < 0.001) among groups categorized by cancer stage, OHA performance status, and mental health. ESs for QLU-C10D were numerically higher for cancer stage, OHA, and performance status (ES = 0.53–1.49), whereas ES was higher for FACT-8D and mental health status (ES = 1.35). Responsiveness was higher for QLU-C10D (AUC = 0.84) compared to FACT-8D (AUC = 0.78). Both QLU-C10D and FACT-8D are valid cancer-specific MAUIs for evaluating patients with HM. However, scholars should consider their slight differences in focus when choosing between the two measures.
- 1 October 2024
- Published by Springer Nature in Health Economics Review
- Vol. 14 (1) , 1-10
Open AccessA comparison of measurement properties between EORTC QLU-C10D and FACT-8D in patients with hematological malignances
To perform a comparison of the measurement properties of two cancer-specific Multi-Attribute Utility Instruments (MAUIs), EORTC QLU-C10D and FACT-8D, in Chinese patients with hematologic malignancies (HM). We conducted a longitudinal study on patients with HM in China, using QLU-C10D and FACT-8D at baseline and follow-up (3–4 months from baseline). We assessed: (i) convergent validity using Spearman’s rank correlation test (r) with EQ-5D-5L; (ii) clinical-groups validity by differentiating cancer stages, overall health assessment (OHA), Eastern Cancer Oncology Group (ECOG) performance status, and mental health status. We also examined clinical validity with effect size (ES) and relative efficiency (RE); (iii) responsiveness to changes in patient self-perception using receiver operating characteristics (ROC) curves and area under the curves (AUC); and (iv) agreement using intraclass correlation coefficients (ICC) and visualized with Bland-Altman plot. Among the 308 patients with HM at baseline, 131 completed the follow-up survey. Agreement between the two measures was high (ICC = 0.76). Both measures were highly correlated with EQ-5D-5 L and significantly differentiated (p < 0.001) among groups categorized by cancer stage, OHA performance status, and mental health. ESs for QLU-C10D were numerically higher for cancer stage, OHA, and performance status (ES = 0.53–1.49), whereas ES was higher for FACT-8D and mental health status (ES = 1.35). Responsiveness was higher for QLU-C10D (AUC = 0.84) compared to FACT-8D (AUC = 0.78). Both QLU-C10D and FACT-8D are valid cancer-specific MAUIs for evaluating patients with HM. However, scholars should consider their slight differences in focus when choosing between the two measures.